This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-26 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Using Mendeleev's nomenclature for unnamed and undiscovered elements, oganesson is sometimes known as eka-radon (until the 1960s as eka-emanation, emanation being the old name for radon). In 1979, IUPAC assigned the systematic placeholder name ununoctium to the undiscovered element, with the corresponding symbol of Uuo, and recommended that it be used until after confirmed discovery of the element. Although widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, the recommendations were mostly ignored among scientists in the field, who called it "element 118", with the symbol of E118, (118), or simply 118. Before the retraction in 2001, the researchers from Berkeley had intended to name the element ghiorsium (Gh), after Albert Ghiorso (a leading member of the research team). The Russian discoverers reported their synthesis in 2006. According to IUPAC recommendations, the discoverers of a new element have the right to suggest a name. In 2007, the head of the Russian institute stated the team were considering two names for the new element: flyorium, in honor of Georgy Flyorov, the founder of the research laboratory in Dubna; and moskovium, in recognition of the Moscow Oblast where Dubna is located. He also stated that although the element was discovered as an American collaboration, who provided the californium target, the element should rightly be named in honor of Russia since the Flyorov Laboratory of Nuclear Reactions at JINR was the only facility in the world which could achieve this result.
== History == Cyclic guanosine monophosphate (cGMP) research began after cGMP and cyclic adenosine monophosphate (cAMP) were identified as cellular components and potentially involved with cellular regulation. Upon the synthesis of cGMP in 1960, progress rapidly spread in the understanding of regulation and effects of cGMP. Earl W. Sutherland received the 1971 Nobel Prize in Medicine for his work with cAMP and secondary messengers. This award sparked extensive research into cAMP, while cGMP received less attention, with its biological functions largely unknown until the 1980s. During this period, two pivotal discoveries highlighted cGMP's role in cellular signaling: atrial natriuretic peptide (ANP) was found to stimulate cGMP synthesis through the particulate guanylyl cyclase (pGC) receptor, and nitric oxide (NO), identified as the endothelium-derived relaxing factor, was shown to activate soluble guanylyl cyclase (sGC), producing cGMP to mediate vasodilation in smooth muscle cells. Further components involved with the cGMP were also identified such as cGMP-hydrolyzing phosphodiesterases (PDEs) and cGMP-binding proteins. The awarding of the 1998 Nobel Prize to Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad for their discoveries in the NO-cGMP pathway renewed interest in cGMP research with the 1st International Conference on cGMP being held in 2003.
Key improvements made after the Union with Ireland Act 1800 (39 & 40 Geo. 3. c. 67) included the illumination of the South Stack Lighthouse in 1809, the construction of a built-up harbour in 1810, and the addition of a substantial breakwater between 1848 and 1873. Although mail service through Holyhead was temporarily suspended in 1838 in favour of rail transport through Liverpool, the development of the north Wales coastal railway in 1850 led to its reinstatement.
Sources: en.wikipedia.org
=== Germanium batteries === The company was developing germanium-based batteries by 2017, citing graphite-free batteries and an electric vehicle battery that fully charges in five minutes, expecting "millions of cars" to be equipped with its electric vehicle battery by 2020. The company announced in 2018 that its mobile phone battery would be commercially available by 2019, and that it had plans to build a battery factory in the United States by 2022. In 2019 it announced the commercialization of a 168-cell germanium-tin battery for electric scooters, and stated that its mobile phone products would be commercially available in late 2020 and the scooter battery would be commercially available in 2021. The company's CEO said its electric car battery would have ten times as many cells as the scooter battery, charge fast enough to add 300 miles of range in under five minutes, and have a cooling system; and that its batteries did not degrade. A 2019 peer-reviewed study concluded that the company's stated battery capabilities have no basis in published, peer-reviewed literature, and listed its unreleased products. Science journalist John Timmer could not identify in 2021 any published research about the company's germanium battery technology.
=== Nano and biological materials === FTIR is also used to investigate various nanomaterials and proteins in hydrophobic membrane environments. Studies show the ability of FTIR to directly determine the polarity at a given site along the backbone of a transmembrane protein. The bond features involved with various organic and inorganic nanomaterials and their quantitative analysis can be done with the help of FTIR.
In an RTG, heat generation cannot be varied with demand or shut off when not needed and it is not possible to save more energy for later by reducing the power consumption. Therefore, auxiliary power supplies (such as rechargeable batteries) may be needed to meet peak demand, and adequate cooling must be provided at all times including the pre-launch and early flight phases of a space mission. While spectacular failures like a nuclear meltdown or explosion are impossible with an RTG, there is still a risk of radioactive contamination if the rocket explodes or the device reenters the atmosphere and disintegrates. For terrestrial RTGs, damage by storms, seasonal ice, or vandalism are potential risks.
{\displaystyle {\begin{aligned}{\frac {\partial \rho }{\partial t}}+\nabla \cdot \left(\rho \mathbf {u} \right)&=0\\\Longleftrightarrow \nabla \cdot \mathbf {u} &=-{\frac {1}{\rho }}{\frac {d\rho }{dt}}={\frac {1}{v}}{\frac {dv}{dt}}\end{aligned}}}
Sources: en.wikipedia.org
=== Chemical industry === J. Peter Grace became CEO and president of Grace in 1945. Under the new leadership, the company began diversifying from the established shipping industry and Latin American operations that it had created. The company went from 60% of sales volume for Latin American operations in the 1950s to 19% of sale volume in 1962. In 1954, the company bought Davison Chemical Company (founded by William T. Davison) and the Dewey & Almy Chemical Company (founded in 1919 by Bradley Dewey and Charles Almy). Chemical sales growth went from 6% of sales in 1950 to 55% in 1977. When J. Peter Grace in 1978 was asked what may have been the best decision by the company, he stated the following:Well, I'd say buying Dewey & Almy. We paid $37 million when it was earning about $1.8 million, at about 20 times earnings. Today, its earning about $60 million.
At first, some major cities or capitals formed local Juntas on the basis of laws from the Hispanic tradition. The armed conflicts started in 1809, with short-lived juntas established to govern in Chuquisaca, La Paz and Quito opposing the government of the Supreme Central Junta of Seville. Although various regions objected to many crown policies, "there was little interest in outright independence; indeed there was widespread support for the Spanish Central Junta formed to lead the resistance against the French". While some Spanish Americans believed that independence was necessary, most who initially supported the creation of the new governments saw them as a means to preserve the region's autonomy from the French. Although there had been research on the idea of a separate Spanish American ("creole") identity separate from that of Iberia, political independence was not initially the aim of most Spanish Americans, nor was it necessarily inevitable. French forces had taken over southern Spain and forced the Supreme Junta to seek refuge in the island-city of Cádiz. The escape to Cádiz and the dissolution of the Supreme Central Junta on 29 January 1810, because of the reverses suffered after the Battle of Ocaña by the Spanish forces paid with Spanish American money, set off another wave of juntas being established in the Americas. These juntas gained their own levels of independence and autonomy from Spain through declarations in 1808–1810.
However, after the East Pakistani Awami League emerged victorious over the Pakistan Peoples Party (PPP), Yahya Khan and the military refused to transfer power. This led to Operation Searchlight, a military crackdown, and eventually sparked the war of liberation by Bengali Mukti Bahini forces in East Pakistan, described in West Pakistan as a civil war rather than a liberation struggle.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.